Cascade Investment Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$392K Sell
426
-47
-10% -$47.6K 0.26% 97
2025
Q4
$508K Hold
473
0.34% 70
2025
Q3
$361K Hold
473
0.24% 97
2025
Q2
$369K Buy
473
+7
+2% +$5.44K 0.26% 88
2025
Q1
$385K Sell
466
-92
-16% -$76.6K 0.3% 76
2024
Q4
$431K Sell
558
-33
-6% -$27.3K 0.31% 72
2024
Q3
$524K Hold
591
0.38% 64
2024
Q2
$535K Sell
591
-200
-25% -$160K 0.42% 56
2024
Q1
$615K Buy
791
+54
+7% +$38.4K 0.46% 53
2023
Q4
$430K Buy
737
+50
+7% +$29.2K 0.35% 71
2023
Q3
$369K Hold
687
0.35% 74
2023
Q2
$322K Hold
687
0.29% 86
2023
Q1
$236K Buy
687
+10
+1% +$3.37K 0.23% 108
2022
Q4
$248K Buy
+677
New +$240K 0.26% 104

Other funds holding LLY

Cascade Investment Group's LLY Position: Q1 2026 in Review

Cascade Investment Group reduced its Eli Lilly (LLY) stake by 9.9% in Q1 2026, selling an estimated $47.6K and leaving 426 shares worth $392K. The position accounts for 0.26% of the portfolio, ranked #97.

Cascade Investment Group first reported a position in LLY in Q4 2022 and has held it in 14 quarters since. The position peaked at $615K in Q1 2024. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Cascade Investment Group held 426 shares of Eli Lilly worth $392K as of Q1 2026.
  • Cascade Investment Group sold 47 Eli Lilly shares in Q1 2026, an estimated $47.6K.
  • Eli Lilly made up 0.26% of Cascade Investment Group's portfolio in Q1 2026, its #97 holding.
  • Cascade Investment Group first reported a position in Eli Lilly in Q4 2022 and has held it in 14 quarters since.
  • Cascade Investment Group's Eli Lilly position peaked at $615K in Q1 2024.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Cascade Investment Group's 13F filing for Q1 2026, filed 13 May 2026.